Patents by Inventor Hassan Javanbakht

Hassan Javanbakht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220125884
    Abstract: Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2R? (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 28, 2022
    Inventors: Manuel Baca, Sarah A. Gilmore, Magdeleine S. Hung, Hassan Javanbakht, Manu Kanwar, Shahzada Khan, Prasenjit K. Mukherjee, Mark R. Nagel, Giuseppe Papalia, Danny W. Tam, Majlinda K. Thomas
  • Publication number: 20220096527
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 31, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
  • Patent number: 11191775
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 7, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun Han, Hassan Javanbakht, Henrik Mueller, Yongguang Wang, Song Yang
  • Publication number: 20210147535
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: August 21, 2020
    Publication date: May 20, 2021
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
  • Patent number: 10829555
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: November 10, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Patent number: 10745480
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 18, 2020
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Publication number: 20200247884
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: April 2, 2020
    Publication date: August 6, 2020
    Inventors: Lykke PEDERSEN, Hassan JAVANBAKHT, Malene JACKEROTT, Søren OTTOSEN, Souphalone LUANGSAY
  • Publication number: 20200048344
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 13, 2020
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Publication number: 20190216846
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 18, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan JAVANBAKHT, Søren OTTOSEN, Lykke PEDERSEN, Henrik MUELLER
  • Publication number: 20190194768
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Application
    Filed: June 19, 2017
    Publication date: June 27, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
  • Patent number: 9949966
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: April 24, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Publication number: 20170283496
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.
    Type: Application
    Filed: March 14, 2017
    Publication date: October 5, 2017
    Inventors: Lykke Pedersen, Hassan Javanbakht, Malene Jackerott, Søren Ottosen, Souphalone Luangsay
  • Publication number: 20160296515
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Patent number: 9458153
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 4, 2016
    Assignee: Hoffmann-La Roche INC.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Publication number: 20160207914
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 30, 2015
    Publication date: July 21, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Publication number: 20160168186
    Abstract: The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein. The application further discloses methods for treatment or prophylaxis of dengue virus mediated diseases with pharmaceutical compositions comprising compounds of Formula I.
    Type: Application
    Filed: October 9, 2015
    Publication date: June 16, 2016
    Inventors: Hassan Javanbakht, Klaus G. Klumpp, Suping Ren, Zhuming Zhang
  • Publication number: 20150210682
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 30, 2015
    Publication date: July 30, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Publication number: 20130018011
    Abstract: The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein. The application further discloses methods for treatment or prophylaxis of dengue virus mediated diseases with pharmaceutical compositions comprising compounds of Formula I.
    Type: Application
    Filed: June 5, 2012
    Publication date: January 17, 2013
    Inventors: Hassan Javanbakht, Klaus G. Klumpp, Suping Ren, Zhuming Zhang